Home' Australian Pharmacist : Australian Pharmacist April 2013 Contents Australian Pharmacist April 2013 I © Pharmaceutical Society of Australia Ltd.
Submit your answers online before
1 June 2013 at www.psa.org.au and
receive automatic feedback, or NZ
members can fax/mail to:
NZCP CPD answers,
PO Box 11 640, Wellington
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions,
4 out of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
1. In the case study, based on the
information available, what is the
patient’s CHADS2 score?
2. In the case study, based on the
information available, what is the
patient’s CHA2DS2-VASc score?
3. In the case study, based on the
information available, what was
the patient’s HAS-BLED score prior
to the admission (excluding the
bleeding on admission)?
4. What is the estimated prevalence of
5. Which ONE of the following is a
direct thrombin inhibitor?
EVIDENCE IN PATIENT CARE
1. Department of Health and Ageing. Review of anticoagulation
therapies in atrial fibrillation. Final Report. 2012. At: www.pbs.gov.au/
2. Bereznicki LR, Peterson GM, Jackson SL, et al. The risks of warfarin use
in the elderly. Expert Opin Drug Saf 2006;5:417–31.
3. Jackson SL, Peterson GM, Vial JH, et al. Outcomes in the management
of atrial fibrillation: clinical trial results can apply in practice. Intern
Med J 2001;31:329–36 .
4. Bereznicki LR, Peterson GM. New antithrombotics for atrial fibrillation.
Cardiovasc Ther 2010;28:278–86 .
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin
in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51.
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in
nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
7. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban
versus warfarin in patients with atrial fibrillation. N Engl J Med
8. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial
fibrillation in adults: national implications for rhythm management
and stroke prevention: The AnTicoagulation and Risk Factors in Atrial
Fibrillation (ATRIA) Study. JAMA 2001;285:2370–5.
9. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of
atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and
implications on the projections for future prevalence. Circulation
10. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory
patients with nonvalvular atrial fibrillation: The anticoagulation
and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med
11. Wong CX, Brooks AG, Lau DH, et al. Factors associated with the
epidemic of hospitalizations due to atrial fibrillation. Am J Cardiol
12. Ninio DM. Contemporary management of atrial fibrillation. Australian
Prescriber 2000;23:100–2 .
13. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial
fibrillation: incidence, risk factors, and prognosis in the Manitoba
Follow-Up Study. Am J Med 1995;98:476–84.
14. Wolf PA, Dawber TR, Thomas HE Jr, et al. Epidemiologic assessment
of chronic atrial fibrillation and risk of stroke: The Framingham study.
Neurology 1978;28:973–7 .
15. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor
to stroke in the elderly. The Framingham Study. Arch Intern Med
16. Morley J, Marinchak R, Rials SJ, et al. Atrial fibrillation, anticoagulation,
and stroke. Am J Cardiol 1996;77:38A–44A.
17. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of
antithrombotic therapy in atrial fibrillation. Analysis of data from five
randomised controlled trials. Arch Intern Med 1994;154:1449–57.
18. Lip GY. Thromboprophylaxis for atrial fibrillation. Lancet 1999;353:4–6.
19. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical
classification schemes for predicting stroke – Results from the
national registry of atrial fibrillation. JAMA 2001;285:2864–70.
20. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke
or death in individuals with new-onset atrial fibrillation in the
community: The Framingham Heart Study. JAMA 2003;290:1049–56.
21. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial
fibrillation for anticoagulation: Stroke risk stratification in patients
taking aspirin. Circulation 2004;110:2287–92.
22. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the
ESC Guidelines for the management of atrial fibrillation: An update
of the 2010 ESC Guidelines for the management of atrial fibrillation.
Developed with the special contribution of the European Heart
Rhythm Association. Eur Heart J 2012;33:2719–47 .
23. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on
anticoagulation control: A systematic review and metaregression.
24. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of
dabigatran compared with warfarin at different levels of international
normalised ratio control for stroke prevention in atrial fibrillation: an
analysis of the RE-LY trial. Lancet 2010;376:975–83 .
25. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics,
pharmacodynamics and tolerability of dabigatran etexilate, a new
oral direct thrombin inhibitor, in healthy male subjects. Br J Clin
Pharmacol 2007; 64:292–303 .
26. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American
College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. 8th edn. Chest 2008;133:234S–56S.
27. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with
atrial fibrillation. N Engl J Med 2011;364:806–17 .
28. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly
patients. Arch Intern Med 2011;171:1285–6 .
29. Wood S. Deaths prompt dabigatran safety advisory in Japan.
Heartwire. 2011. At: www.medscape.com/viewarticle/748143?sssd
30. Wall T. Pradaxa deaths probed. 2011. At: www.stuff.co.nz/national/
31. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med
32. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and
prediction of adverse events in patients with atrial fibrillation: a
systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84–91.
33. Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation control in
Sweden: reports of time in therapeutic range, major bleeding, and
thrombo-embolic complications from the national quality registry
AuriculA. Eur Heart J 2011;32:2282–9 .
34. Therapeutic Guidelines. eTG Complete: Cardiology. 2012.
35. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial
fibrillation: Antithrombotic therapy and prevention of thrombosis.
9th edn. American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines. Chest 2012;141:e531S–75S.
36. Therapeutic Goods Administration. Dabigatran (Pradaxa) and risk
of bleeding: Information for health professionals. Updated safety
information. 8 Feb 2013.
37. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding
anticoagulation for atrial fibrillation: a systematic review. Age Ageing
38. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke
prevention therapy in patients with atrial fibrillation: the atrial
fibrillation investigators. Stroke 2009;40:1410–6 .
39. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism
and bleeding with thromboprophylaxis in patients with atrial
fibrillation: A net clinical benefit analysis using a ‘real world’
nationwide cohort study. Thromb Haemost 2011;106:739–49.
Links Archive Australian Pharmacist March 2013 Australian Pharmacist May 2013 Navigation Previous Page Next Page